Anales de la RANM

196 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 IMPACTO DEL COVID-19 EN EL CAMPO DE LA ONCOLOGÍA Mariano Provencio Pulla An RANM · Año 2020 · número 137 (02) · páginas 190 a 197 15. WHO. Laboratory testing for 2019 novel coronavi- rus (2019-nCoV) in suspected human cases. 2020. https:// www.who.int/publicaciones. 20200117 (accessed March 13,2020). 16. Liu Y, Yan L-M, Wan L et al. Viral dynamics in mild and severe cases of COVID-19. Lancet Infect Dis 2020; 20(6):656–657. 17. Yang X, Yu Y, Xu J et al. Clinical course and out- comes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med 2020; 8(5):475–481. 18. Provencio M, Carcereny E, Rodríguez-Abreu D et al. Lung cancer in Spain: information from the Thoracic Tumors Registry (TTR study). Transl Lung Cancer Res 2019; 8(4):461–475. 19. Chen N, Zhou M, Dong X et al. Epidemiological and clinical characteristics of 99 cases of 2019 nov- el coronavirus pneumonia in Wuhan, China: a de- scriptive study. Lancet 2020; 395(10223):507–513. 20. Suresh K, Naidoo J, Lin CT, et al. Immune Check- point Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. Chest 2018; 154(6):1416–1423. 21. Li K, Wu J, Wu F et al. The Clinical and Chest CT Features Associated With Severe and Criti- cal COVID-19 Pneumonia. Invest Radiol 2020; 55(6):327–331. 22. Wu J, Wu X, Zeng W et al. Chest CT Findings in Patients With Coronavirus Disease 2019 and Its Relationship With Clinical Features. Invest Radiol 2020; 55(5):257–261. 23. Zhao W, Zhong Z, Xie X et al. Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol 2020; 214(5):1072–1077. 24. Kay F, Abbara S. The many faces of COVID-19 SPECTRUM OF IMAGING MANIFESTATIONS. Radiology: Cardiothoracic Imaging 2020. Mar 23. 2020 .https://doi.org/10.1148/ryct 2020200152. 25. Shi H, Han X, Jiang N et al. Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis 2020; 20(4):425–434. 26. Suh CH, Kim KW, Pyo J et al. The incidence of ALK inhibitor-related pneumonitis in advanced non- small-cell lung cancer patients: A systematic review and meta-analysis. Lung Cancer 2019; 132:79–86. 27. Hida T, Nokihara H, Kondo M et al. Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open- label, randomised phase 3 trial. Lancet 2017; 390(10089):29–39. 28. Peters S, Camidge DR, Shaw AT et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med 2017; 377(9):829–838. 29. Gettinger SN, Bazhenova LA, Langer CJ et al. Ac- tivity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignan- cies: a single-arm, open-label, phase 1/2 trial. Lancet Oncol 2016; 17(12):1683–1696. 30. Camidge DR, Kim HR, Ahn M-J et al. Briga- tinib versus Crizotinib in ALK-Positive Non- Small-Cell Lung Cancer. N Engl J Med 2018; 379(21):2027–2039. 31. Yoneda KY, Scranton JR, Cadogan MA et al. Inter- stitial Lung Disease Associated With Crizotinib in Patients With Advanced Non-Small Cell Lung Cancer: Independent Review of Four PROFILE Trials. Clin Lung Cancer 2017; 18(5):472–479. 32. Terbuch A, Tiu C, Moreno Candilejo I et al. Radio- logical patterns of drug induced interstitial lung disease (DILD) in early phase oncology clinical trials. Clin Cancer Res 2020. doi:10.1158/1078- 0432.CCR-20-0454. 33. Sud A, Jones M, Broggio J, et al. Collate- ral damage: the impact on cancer outcomes of the COVID-19 pandemic. medRxiv. Doi. org/10.1101/2020.04.21.20073833 . 34. Liang W, Guan W, Chen R et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020; 21(3):335–337. 35. Lei S, Jiang F, Su W et al. Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 in- fection. EClinicalMedicine 2020; 21:100331. 36. Wu Z, McGoogan JM. Characteristics of and Im- portant Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chine- se Center for Disease Control and Prevention. JAMA 2020. doi:10.1001/jama.2020.2648. 37. Hanna TP, Evans GA, Booth CM. Cancer, CO- VID-19 and the precautionary principle: priori- tizing treatment during a global pandemic. Nat Rev Clin Oncol 2020; 17(5):268–270. 38. Chen Z, King W, Pearcey R et al. The relationship between waiting time for radiotherapy and clini- cal outcomes: a systematic review of the literatu- re. Radiother Oncol 2008; 87(1):3–16. 39. Raphael MJ, Biagi JJ, Kong W et al. The relation- ship between time to initiation of adjuvant che- motherapy and survival in breast cancer: a sys- tematic review and meta-analysis. Breast Cancer Res Treat 2016; 160(1):17–28. 40. Zhang L, Zhu F, Xie L et al. Clinical characteris- tics of COVID-19-infected cancer patients: a re- trospective case study in three hospitals within Wuhan, China. Ann Oncol 2020; 31(7):894–901. 41. Rogado J, Pangua C, Serrano-Montero G et al. Covid-19 and lung cancer: A greater fatality rate? Lung Cancer 2020; 146:19–22. 42. Garassino MC, Whisenant JG, Huang L-C et al. COVID-19 in patients with thoracic malignan- cies (TERAVOLT): first results of an internatio- nal, registry-based, cohort study. Lancet Oncol 2020; 21(7):914–922. 43. Wang H, Zhang L. Risk of COVID-19 for patients with cancer. Lancet Oncol 2020; 21(4):e181. 44. Lai J, Ma S, Wang Y et al. Factors Associated With Mental Health Outcomes Among Health Care Workers Exposed to Coronavirus Disease 2019. JAMA Netw Open 2020; 3(3):e203976. 45. Wu Y, Wang J, Luo C et al. A Comparison of Burnout Frequency Among Oncology Physi- cians and Nurses Working on the Frontline and Usual Wards During the COVID-19 Epidemic in Wuhan, China. J Pain Symptom Manage 2020; 60(1):e60–e65. 46. ASCO. ASCO coronavirus resources. https:// www.asco.or/asco-coronavirus-information 2020.